Illumina unveils new gene sequencing device with bargain price tag

Illumina is rolling out its latest gene sequencing machine, the iSeq 100, priced at just under $20,000.

Illumina, the maker of DNA sequencers, unveiled its latest device. With a price tag of just under $20,000, the company hopes it will open the doors for more researchers to study viruses, bacteria and other microbes.

The company’s new iSeq 100 sequencing device, which measures about 1 cubic foot, is priced at $19,900. It combines Illumina’s sequencing by synthesis chemistry with metal-oxide-semiconductor detection technology.

The device, which Illumina touts as being the most powerful of its type for its size, is part of an effort to position next-generation gene sequencing as a standard for discovery research and routine genomic testing for a wide range of customers, markets and applications.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Now “any researcher can have access to the accuracy of an Illumina sequencer in their lab,” Francis deSouza, Illumina’s president and CEO, said in a statement. “The iSeq 100 offers robustness and reliability for a broad range of applications ranging from germline and somatic tumor profiling to 16S microbial analysis and targeted gene expression.”

The device is expected to begin shipping in the first quarter, the company said, adding that it is working to increase the device’s output and reduce its run time in an effort to expand the iSeq 100 into other markets like rapid microbiome sequencing, testing for foodborne pathogens and monitoring hospital acquired infections.


Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.